





















Submitted in partial fulfillment of the requirements for 








I, Naseera Allie hereby declare that the work on which the dissertation is based 
on is original and is my own unaided work carried out by me under the 
supervision of Dr M Moodley. This work has not been submitted previously to this 













I, Dr Naseera Allie would like to extend my gratitude to the following people: 
 
1.  Dr M Moodley,Head of Gynaecology Oncology  Unit at Inkhosi Albert 
Luthuli Central Hospital for his expert advice and guidance in helping me 
compile this dissertation. 
 
2. To all the health care workers who were willing to be interviewed. 
 
 
















Table of Contents 
 
ABSTRACT                 i 
 
Chapter 1 CERVICAL CANCER            1 
 
 
Chapter 2 HUMAN PAPILLOMAVIRUS (HPV)          4 
 
 
Chapter 3 CERVICAL CANCER SCREENING          7 
 
 
Chapter 4 HPV VACCINE            10 
 
 
Chapter 5 STUDY: AIMS, METHODS AND STATISTICS        19 
 
 
Chapter 6 RESULTS             23 
 
 
Chapter 7 DISCUSSION            27 
 
 

























Appendix A Questionnaire                             35 
     
 
Figure 1 Age standardized Incidence rates                     36 
 
 
Table I Demographics of Health care workers                        37 
 
 
Table II Knowledge and awareness of the human papillomavirus 
           vaccine among  healthcare workers                    38 
 
 
Table III Demographics of healthcare workers awareness of the human  
papillomavirus avaccine            39 
 
 
Table IV Uptake of the human papillomavirus vaccine amongst  
providers aware of the vaccine           40 
 
 





























To determine if health care workers are aware of the HPV vaccine and its 
availability, uptake of the vaccine and prescribing practices and reasons for non 




Health care providers working in the private sector, in the Ethekweni health 
district in Kwazulu Natal, were interviewed.  Health care workers included: 100 
general practitioners, 50 gynaecologists, 50 paediatricians, 50 medical staff and 
50 nursing staff.  A questionnaire was designed for purpose of this study.  Visits 
were be made to health care providers.  All heath care providers who were willing 
to participate were interviewed.  
 
STATISTICS 
Comparisons of awareness among subgroups of health care providers was 
analysed using Chi-square tests. If significant, pairwise comparisons were made 
using a Bonferroni adjustment for multiple comparisons. Associations between 
awareness and other factors, such as demographic, uptake and beliefs were 
tested using a chi square test. Analysis was done by Stata v11 (StataCorp, 2009)        
            










Three hundred health care workers were interviewed - 50 gynecologists (16.7%), 
52 pediatricians (17.3%), 99 general practitioners (33%), 49 other medical 
doctors (16.3%) and 50 (16.7%) nurses. Two hundred and sixty seven health 
care workers (89%) were aware of the HPV vaccine and one hundred and eighty 
eight health care workers (70.4%) informed patients of the availability of the HPV 
vaccine. Most (77.9%) practitioners have only prescribed the vaccine less than 
ten times. Gardasil® was prescribed by 46%, Cervarix® by 6.5% and prescription 
of either vaccine of health care workers was 50.2%. Practitioners were generally 
unaware that Gardasil® could be prescribed to males (62.9%). 
 
CONCLUSION 
Health care workers were aware of the HPV vaccine and prescribed the vaccine 
on request. However even though practitioners were aware of the vaccine, most 
have prescribed the vaccine less than ten times since licensing in 2008. 






             
 








Cancer of the cervix is the second most common cancer worldwide and accounts 
for approximately 80% of cases in developing countries.1 In South Africa cervical 
cancer has an overall age standardized incidence rate (ASIR) of 22 per 100,000 
cases per year and is the most common cancer amongst females.1, 2 There are 
approximately 5743 new cases of cancer of the cervix diagnosed every year in 
South Africa and about 3027 women die of the disease each year.2 Over the past 
few years the cervical cancer prevalence and mortality rates in the United States 
have decreased mostly as a result of cytological screening.  Despite this, 
approximately 10 400 new cases of invasive cancer of the cervix and 3700 
deaths occurred from the disease in 2005 in the United States.3 This is contrary 
to the high incidence in the developing world of cervical cancer and is an 
indication of poor access to health care resources.4 The incidence of cervical 
cancer in 2000 was 471,000 new cases; of which the mortality was 233, 000 
cases worldwide.5  Eighty per cent of cases occurred in developing countries 
although they have less than 5% access to the global cancer care resources. 
The age standardised incidence rates (ASIR) of cervical cancer in Southern 
African countries is shown in Figure 1.2  South Africa has a rate of 26.6 cervical 
cancer cases per 100, 000 women per year; however Swaziland and Lesotho 




women per year of cervical cancer cases respectively. Differences can be 
attributed to different levels of cervical screening.  Data collection is limited in 
numerous third world countries and the existing data is likely an underestimate of 
the true incidence of disease.  
 
A pathology-based cancer registry was launched in South Africa in 1986. The 
information was obtained from laboratory reports in both public and private 
sectors. In 1986, the cancer registry showed that of all the cancers reported in 
women, 16, 559 were incident cases which comprised  2,897 (17.4%) of 
histologically confirmed cervical cancers.6  In the South African cancer registry of 
1993–1995, approximately  3,387 annual  incident cases of cervical cancer were 
reported.7 Mortality of women with cervical cancer for the year 1994 was reported 
to be 1,497. The age standardized incidence rate of cancer of the cervix in 1994 
was 22/100,000.  This figure was subdivided according to race groups - African 
females had a rate of 27/100,000. These represented the most disadvantaged 
women in South Africa in terms of health care access. Black African women had 
a lifetime risk of 1 in 34 for developing cervical cancer which is in contrast to 1 in 
93 for White women.  
 
A study performed in 2002 reflected the occurrence of cervical cancer in Black 
African women in Durban.8 For women living in urban areas the age 
standardized incidence rate was 45/100,000 and two thirds of the lesions were 





The figures will most likely change as data have shown that HIV (Human 
Immunodeficiency Virus) positive women have a higher risk of developing pre-
cancerous lesions and cancer of the cervix.9  Another study reported an 
accelerated clinical progression of premalignant cervical lesions to invasive 
cervical carcinoma in HIV-infected females.10  In 1993 cervical cancer was 
included as one of the defining conditions of the acquired immune deficiency 
syndrome (AIDS).11 A local study conducted in Durban, South Africa 
demonstrated a HIV prevalence of 21% in women with cervical cancer.12 It was 
also found that women who were HIV-seropositive were about 15 years younger 
than women who were HIV-seronegative, however the stage of disease at 
presentation did not differ significantly. The available evidence suggests that the 
expression of HPV (Human papillomavirus) infection is greater in HIV infected 
women and the rate of progress is more rapid from initial HPV infection to the 
development of cancer of the cervix.13 It has also been shown that women who 
are infected with high risk HPV subtypes and HIV have a 40 fold increased risk of 










   CHAPTER 2 
 
Human papillomavirus (HPV)  
 
Human papillomavirus (HPV) is a small, double-stranded deoxyribonucleic acid 
(DNA) virus containing eight genes. HPV- related disease can occur at various 
locations in the body. In the female genital tract the most common association is 
cancer of the cervix and its precursor, cervical intra-epithelial neoplasia (CIN).15 
Other associations with HPV include anal, vaginal and vulval intraepithelial 
neoplasia (AIN,VAIN, VIN) as well as other cancers.Although these are not as 
common as CIN, they can also progress into invasive diseases at these sites. In 
the male genital tract HPV is associated with anal disease (AIN), penile cancer 
and penile intraepithelial neoplasia (PIN). HPV infection in males and females 
can also lead to genital warts which are benign. Other HPV related diseases can 
occur in epithelial tissues such as skin or mucous membranes of the head and 
neck where it can cause oro-pharyngeal cancers.11  
 
The HPV types can be categorised into groups depending on the risk of 
oncogenicity.  In 2003 described high risk (HR) and low risk (LR) groupswere 
described.16 High risk HPV types include HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 66 and 68. Low risk types include HPV 6, 11, 42, 43 and 44.16 
HPV types 16 and 18 are the causative agent in approximately 70% of cervical 




33, 35, 45, 52 and 58. Adenocarcinomas are largely associated with HPV 18 and 
HPV 45.17 In South Africa  HPV 16 and 18 has been found to be the most 
prevalent in cervical cancer. 18 
 
Infection with HPV is endemic in sexually active populations. After a sexual 
encounter the exposure to HPV peaks with a prevalence of 20-60%. By the age 
of 50 years approximately 80% of women who are sexually active would have 
been infected with HPV. HPV infection is transient as it has been shown by 
epidemiological studies that about 90% of infections do not cause major illness. 
Data have shown that after an infection, 50% of females will have a negative test 
at six months, 70% at one year and 80-92% at two years.16 The body’s natural 
immune response clears the infection. It is less likely that a transient infection will 
cause high grade CIN than a persistent infection. Infections which are transient 
can lead to low grade CIN (CIN 1) preceding the body’s ability to clear the virus.  
Persistent infection is caused by high risk subtypes rather than low risk subtypes. 
 
Infection which is persistent over a long period of time, can lead to high grade 
cervical intraepithelial neoplasia (CIN 2 or 3) and cancer of the cervix. Viral 
infection that persists with mainly high risk types (e.g. HPV 16 and 18), enhances 
the risk of high-grade CIN (CIN 2 or 3) and cancer of the cervix. Spontaneous 
regression can occur in high grade CIN; although the current management is to 
treat the lesions. High grade CIN lesions can progress to cervical cancer.  In an 




infections but in a population that is screened the risk is reduced to 1-2%. 
Immunocompromised patients e.g.HIV infected and immunosuppressive 


























Cervical Cancer Screening 
 
Prevention of cervical cancer includes primary and secondary prevention. 
Decreased exposure by altering sexual practices (e.g., monogamy for life and the 
use of barriers contraception) and vaccination are included in primary prevention. 
Papanicolaou (pap) smears for precancerous lesions, screening for HPV, and 
removal of HPV-infected precancerous lesions by laser, cryosurgery, large loop 
excision of the transformation zone (LLETZ) and cervical cone biopsy are 
included in the concet of secondary prevention.19 
 
Cervical cancer is the most prevalent cancer; however it can be prevented 
through screening and treatment of cervical intraepithelial neoplastic lesions.20 
Cervical cancer could very well be almost eliminated in South Africa if screening 
and treatment were sufficient.21  Mortality related to cervical cancer has been 
decreasing in developed countires through screening programmes and treatment 
of early lesions. Implementation of nationwide screening in the 1960’s in Nordic 
countries has shown a decrease in trend in cervical cancer. Iceland had the 
greatest fall (84% from 1965 to 1982) where there screening interval was the 
shortest and the target age ranges the widest.22 In Norway 5% of the population 





Screening programmes in resource- poor settings have been hard to introduce.23 
Barriers to implementation include:  reduced awareness of the disease and the 
role of screening; failure of women to avail themselves for screening; low budget 
allocation for screening purposes and the demands of challenging health needs 
such as HIV infection, tuberculosis and other common diseases. 
 
South Africa only implemented a national cervical cancer screening policy since 
the 1990’s. Screening of the cervix, mainly in antenatal and family planning 
clinics were carried out opportunistically. This reached mainly women who were 
younger and who were not the target group who would most benefit from 
screening as they have reduced rates of diseases of the cervix than women who 
are older.24,25 In 2000 the South African National Department of Health 
recognized cervical cancer as a national health priority.  A national cervical 
screening policy was launched.  The policy states that all women attending public 
sector services are allowed three free Papanicolaou smears in their lifetime 
starting at the age of 30, 10 years apart. The programme was expected to 
decrease the incidence by half of cervical cancer if it achieved over 75% 
coverage and this is assumed 100% coverage of the population.24 In KwaZulu-
Natal in 2005,  28 760 smears were performed, accounting for only 26% of the 
number of targeted smears for 2006 and 2007. In South Africa, during 2005–06, 
100% of clinics offering primary health care had health care workers educated to 




economic load is considerable with treatment of cervical intraepithelial neoplasia 
lesions and the follow-up of false-positive cervical cytology.27  
 
No statistics are available from the private sector of South Africa, although the 
impression is that women are over-screened. This practice is thus only available 

























Primary prevention of cervical cancer involves prevention of de novo HPV 
infection of the cervix. Vaccination against certain HPV types is potentially an 
effective method. 
 
Two prophylactic HPV vaccines developed recently aims at primary prevention. 
These vaccines are recombinant adjuvant adsorbed and include a bivalent 
vaccine targeting HPV 16 and 18 (Cervarix®; GlaxoSmithKline) and a 
quadrivalent vaccine targeting HPV 16, 18, 6 and 11 (Gardasil®; Merck, Sharpe & 
Dohme). These vaccines have shown sustained efficacy and safety profiles up to 
7 years. Three doses need to be administered over a six month period to ensure 
effective pharmocodynamics.28, 29 The vaccines have been licensed in March 
2008 for use in South Africa and are currently only available in the private health 
sector. It is recommended for girls 11 to 12 years old, but Gardasil® is approved 
for females 9 to 26 years and males 9 to 17 years. Cervarix® is approved for 
females aged 9 to 26 years. For maximal efficacy the vaccine must be given 
before sexual debut and thus before the possible exposure to HPV.30 Recently 
(November 2010), the Food and Drug Association (FDA) approved a new 
indication for Gardasil® viz, it may be used to prevent cancer of the anus caused 




(AIN) grades 1, 2, and 3 (anal dysplasias and precancerous lesions) caused by 
HPV types 6, 11, 16, and 18, in males and females aged 9 to 26 years.30 
 
The vaccines have been extensively assessed in placebo-controlled trials and 
have shown to be effective and resulted in a more than 90% reduction in the 
number of persistent infections and HPV-associated genital diseases which are 
caused by the types of HPV included in the vaccines.32 If a persistent HPV 
infection has already developed the vaccine may not be as effective. A major 
source of protection afforded by the vaccines is believed to be serum neutralising 
antibodies.34, 35 After naturally acquired infection the concentration of antibodies 
are low.36 Females who have acquired naturally HPV infection remain at risk for 
infection with the identical HPV type. This is possible since antibody 
concentrations after infection acquired naturally are insufficient to offer 
protection.34 Poor antibody assay specificity could be attributed to these results. 
A study has shown a sustained high concentration of IgG antibody to HPV 16 
after infection acquired naturally resulting in a decreased risk of successive 
infection with HPV 16 and related types, but those with a lower concentration of 
IgG antibody did not have protection.36 In the absence of a serological correlate 
of protection, higher neutralising antibody concentrations should be induced by 
vaccination than infection acquired naturally.37,38 To date (>7 years) the vaccine 






Quadravalent HPV 6/11/16/18 L1 Virus like particle vaccine (Gardasil®) has been 
evaluated in 2 large randomized control trials – FUTURE (Females United To 
Unilaterally Reduce Endo/ectocervical disease) II and I.40,41 Findings from 
FUTURE II trial have shown that the HPV-16/18 AS04-adjuvanted vaccine in 
healthy females aged 15–25 years provided a high, sustained efficacy for the 
development of CIN 2 or 3, adenocarcinoma in situ and cervical cancer. The 
FUTURE I trial showed an efficacy of 100% in preventing anogenital disease in 
women who were HPV naïve. Vaccine efficacy was 100% in preventing CIN 
grades 1 to 3 or adenocarcinoma in situ. Secondary analyses of data from the 
FUTURE trials demonstrated partial protection against acquisition of the non 
vaccine HPV types (HPV31/33/45/52/58).  In both FUTURE trials, no evidence 
was found that vaccination changed the course of disease or infection in women 
who had evidence of HPV infection at the time of receipt of the first dose of 
vaccine. This data reinforce the use of the HPV vaccine to prevent infection 
rather than treatment of pre existing HPV infection. 
 
Cervarix®  has been evaluated in one large, randomized clinical trial – PATRICIA 
(Papilloma trial against cancer in adults) 42 and an autonomous US National 
Cancer Institute (NCI).43 In the PATRICIA trial vaccine efficacy for the prevention 
of CIN 2 or 3, adenocarcinoma in situ, or cervical cancer was 93%. Vaccine 
efficacies for the prevention of incidentally-detected 6 month and 12 month 
persistent infections by HPV 16/18 were 94% and 91%, respectively. Cervarix® 




(HPV31/33/45/52/58). The vaccine is used to prevent infection rather than as a 
treatment for pre- exsiting infections and related diseases.  Excellent antibody 
responses have been reported with Cervarix®, with sustained high antibody 
concentrations after 6.4 years follow up. Assessment of the immunogenicity of 
the quadravalent and bivalent vaccines,44  showed that immunization by 
Cervarix® induced  titres of serum neutralizing antibodies 2.3 to 4.8 fold higher for 
HPV 16 and 6.8 to 9.1 fold higher for HPV 18. The long term duration of 
protection is however unknown. 
 
A schedule for dosing which is a possible alternative to the standard schedule 
has been compared in healthy females aged 15 to 25 years. The results 
indicated that the third dose of the HPV-16/18 vaccine can be given any time 
between 6 and 12 months after the first dose resulting in immunogenicity which is 
adequate as well as having an acceptable clinical safety profile.45 
 
There are concerns about an increase in unsafe sex practices and possible false 
impression that HPV vaccine would confer protection against other sexually 
transmitted infections (STIs). A possible theoretical risk of the HPV vaccine is a 
reduction of cytological screening for cancer of the cervix arising from the belief 
that screening is unnecessary. This might occur as a result of an inaccurate 
belief that prevention by screening is not needed or due to uncertainty about 
Papanicolaou smear schedules which may alter after extensive use of the 




infected with HPV types 16 and 18. The vaccine is not 100% effective as other 
HPV types can also cause cervical cancer are not included in the vaccines. 
 
Neither HPV vaccine should be routinely given during pregnancy. However if a 
patient is found to be pregnant and has already received a vaccine, the 
remaining doses should be given after pregnancy completion. Further studies are 
required to determine the actual risk.46 
The effectiveness of the HPV vaccine uptake will depend largely upon whether 
providers advise the vaccine to patients and are able to attain high rates of 
immunization.47 Health benefits will be likely with large-scale acceptance 
resulting in a decreasing morbidity and mortality associated with cervical cancer 
and by decreasing the psychosocial burden of both genital warts and abnormal 
cytological smear results.48 An important step to establish an effective vaccine 
delivery program is to be aware of providers’ intention to recommend and 
prescribe immunization.49 There are several factors associated with the likelihood 
of providing the HPV vaccine i.e. characteristics of the provider, or that of the 
practice and knowledge and attitudes about HPV vaccination.49 Despite studies 
revealing that clinicians are likely to recommend the HPV vaccine there are 
limitations with regard to recommendations for younger adolescents.44 These are 
related to the physician’s characteristics, knowledge, and attitudes about HPV 
vaccines.50  Physician-attitudes regarding HPV vaccines may differ from those 




immunizing children against sexually transmitted infections (STIs), or poor 
communication with preadolescents regarding sexually transmitted infections. 
Provider attitudes may be related to the disease targeted (cervical cancer vs. 
genital warts) or patient characteristics.50 
 
Pediatricians’ views regarding successful HPV vaccine delivery plans is 
important given their vital role in other vaccinations to children and their 
extensive clinical knowledge of  vaccines in children. Pediatricians play an 
important role in HPV vaccine delivery to adolescents as they are more likely to 
seek medical care from a pediatrician than any other health care worker.50 HPV 
vaccine uptake could be affected by factors associated with patient-provider 
communication. Studies show that the quantity and accuracy of the information 
presented by providers and patients’ personal experience may persuade patient 
and caregiver acceptance of the vaccines. 
 
Preventing cervical cancer with the HPV vaccine will only be realised if the 
vaccination is extensively implemented. HPV vaccines have received media 
support and health care physicians working in the private sector have approved 
its use. Immunization would be most beneficial to the developing countries, 
where women do not have access to clinics to have regular Papanicolaou 
smears. Challenges in developing countries could possibly be due to cost of the 
vaccine, distribution as well as access to the vaccine and personal beliefs with 




availability represent important system-based factors that could prohibit vaccine 
uptake.52 An important issue to address is the cost as at present in Durban, the 
Gardasil® vaccine is priced at R902 and Cervarix® R518 per injection. If the 
vaccine could be made available at a significantly reduced cost, uptake of the 
vaccine would be improved. The HPV vaccine has been shown to be a highly 
cost-effective health intervention especially when compared to cost of treatment 
of cervical cancer .53 Treatment of cervical cancer may be required for many 
months after diagnosis, especially for women with late-stage cancers. The cost of 
diagnosis and treatment of stage I cervical cancer is R29,997 per woman  vs. 
stage IV  R55,997 per woman. 54 
 
 
The promotion of the HPV vaccine is important to its acceptance and compliance 
amongst young females and parents. The belief that a vaccine against an STI 
might promote unsafe sexual behavior has received interest in the media.55, 56, 57 
Currently it is uncertain whether vaccination would promote unsafe behavior. 55 
The resistance to implementation of the vaccine could potentially be overcome 
with sufficient advice and information. The focus should be on the vaccines 
preventive properties against cervical cancer.58 At present interventions such as 
providing adolescents with condoms and emergency contraception has not 





Implementing the vaccine in developing countries is associated with a number of 
limitations. Countries mostly lacking the resources to attain effective screening 
programmes would therefore benefit from the extensive rollout of a preventive 
HPV vaccine. Interventions that do not have an immediate impact on health care 
can only be funded if the benefits are worth the expense. The reduction of 
cervical intraepithelial lesions over the next few years will be small and priority to 
vaccinate will therefore be low.61 
 
As mentioned the high cost of the vaccine is concerning as this has implications 
for vaccination programs as cancer of the cervix is important among females 
from disadvantaged populations. In low income countries the HPV vaccines may 
not be affordable.62  A South African study showed the addition of the HPV 
vaccine to the present cervical cancer screening policy can be cost effective.62 
HPV vaccines can most likely decrease the cost to the health system as well as 
reduce the cost to the patient. 
 
It is still important to have a functional screening programme which is aimed at 
secondary prevention, as cancer of the cervix is not completely eliminated by 
vaccination against HPV, but instead the risk is decreased. In settings with low 
screening coverage like South Africa, where screening is less than 50% and 
treatment of cervical intraepithelial neoplastic lesions is well below 100%, the 





The rationale for undertaking this research project was to establish the 
awareness, knowledge and utilization of the HPV vaccine amongst different 
health care workers. Practitioners in obstetrics and gynecology normally care for 
females who have developed the sequelae of HPV infection and they would 
therefore be critically involved in preventing HPV infection.  General practitioners 
will play a major role in preventing HPV-related disease by the vaccination of 
girls and young women aged 9 to 26 years as well as provide primary care to 
children. Pediatricians will play a role in education of the HPV vaccine as girls 
and early adolescents  are likely to visit a pediatrician. Their recommendation is 
likely to influence parent’s or adolescent’s decision to receive the vaccine. 
Nurses play a role in primary health care and therefore should provide valuable 
information to adolescents and parents with regards to the HPV vaccine. In 
addition other medical professionals may also be faced with the chance to 
recommend or prescribe the HPV vaccine when given the opportunity.  It is 
therefore important to assess knowledge and uptake of the HPV vaccine 











     CHAPTER 5 
 






The aim of this study was to examine the knowledge, attitudes and utilization of 
the HPV vaccines amongst health care workers - gynecologist, pediatricians, 
general practitioners, nurses and other medical professionals. 
 
 
Materials and Methods 
 
The research protocol was approved by the University of Kwazulu Natal (UKZN) 
College of Health Sciences postgraduate committee and UKZN biomedical 










The study population consisted of a random sample of 300 health care providers. 
This included 100 general practitioners, 50 gynaecologists, 50 paediatricians, 50 
other medical staff and 50 nursing staff.  
 
A sample size of 256 health care providers was required to measure the 
awareness of the HPV vaccine to within ± 6% with a probability of 95% assuming 
an awareness of 50%. A stratified sample was selected. Awareness among 
general practitioners can be estimated to within ± 11% and to within ± 15% for 
the other groups. If a non-response rate of 15% is assumed, a sample size of 




Health care providers (pediatricians, general practitioners, obstetricians, medical 
staff and nursing staff) in the Ethekweni health district in Kwazulu Natal were 
interviewed. Other medical staff included specialists (excluding pediatricians and 
gynecologists) in other fields e.g. anesthetists and physicians. The interviews 
were conducted between July 2010 and December 2010. As the vaccine is 
currently only available in the private sector since March 2008, only private 
practitioners were interviewed. Interviews were conducted in clinicians’ rooms as 




participants in the study were asked to fill out a questionnaire at the time of the 
interview. The questionnaire was based on semi- structured and structured 
questions (see appendix A).  The responses were anonymous. Participants were 
assured that individual information would be private and anonymity maintained. 
Important aspects explored included: knowledge of current cervical screening 
policy in South Africa, awareness of the HPV vaccine; target populations and 
profile of patient that the HPV vaccine would be prescribed to; and patient and 
prescribers beliefs.  
 
Limitations of the study were that only practitioners practicing in the private 
sector were interviewed. Ethical considerations included:  no direct patient 
interaction, only health care providers who consented to participate in the study 
were interviewed, the questionnaire had numbers for references and no names 
of practitioners were recorded and all the information obtained were kept 













DATA/ STATISTICAL ANALYSIS TECNIQUES:   
Data regarding the number and reasons for refusals or non participation will be 
presented and where possible compared to those participating to determine any 
non-response bias. Frequencies and percents will be presented for all categorical 
data including 95% confidence intervals. All data was categorical and all 
comparisons were made using categorical data. 
 
Comparisons of awareness among subgroups of health care providers were 
analysed using Chi-square tests. If significant, pairwise comparisons were made 
using a Bonferroni adjustment for multiple comparisons. Associations between 
awareness and other factors, such as demographic, uptake and beliefs were 
tested using a chi square test. A sub analysis of prescribing practices of those 
using the HPV vaccine will also be presented. Sub group comparisons and tests 
of association were done using Chi Square tests or exact tests as above. 
Reasons for not prescribing were collected in an open ended question, coded 
and reported.  
 
Data was entered into Excel.  All open ended questions were coded prior to data 
















Three hundred health care workers were interviewed - 50 gynecologists (16.7%), 
52 pediatricians (17.3%), 99 general practitioners (33%), 49 other specialists 
(16.3%) and 50 (16.7%) nurses.  The provider characteristics in terms of age, 
gender, time practicing and patients being  either medical or cash paying are 
shown in Table I. Most of the interviewed health care providers were in the age 
group 40-60 years (53%). The HPV vaccine was commonly prescribed by health 
care workers practicing for 10-20 years  (46%). Most health care workers were 
treating patients who had medical aid, rather than cash-paying patients (65.7% 
vs. 34.3%).  
 
The results indicated that 93% of health care workers were aware of the cervical 
screening programme in South Africa (Table II). One hundred and eighty one 
health care workers (60.3%) informed patients of HPV- related diseases. Most 
nurses (82%) and gynaecologists (76%) informed patients about the HPV- 
related illnesses.  
 
Two hundred and sixty seven health care workers (89%) were aware of the HPV 
vaccine (Table II).  One hundred and eighty eight health care workers (70.4%) 
informed patients of the availability of the HPV vaccine (Table II). There were 231 




not prescribe the vaccine reasons given were either that patients did not request 
the vaccine – 27%, they did not see patients that needed the vaccine – 30.6%, it 
did not come up in consultation – 22.2% and it was for the gynaecologist to 
prescribe – 11.1%.  If they did prescribe the vaccine the target age group were 
females aged 9-26 (58.9%), sexually active patients – 8.2%, females of any age 
– 22.5% and on request only -10.4%. If health care workers were prescribing the 
vaccine, the number of times the vaccine was used was mostly less than 10 
times (77.9%). 
 
The specific HPV vaccine health care workers prescribed are shown in Table II. 
The results indicated that Gardasil® was prescribed by 100 health care workers 
(43.2%), Cervarix® by 15 health care workers (6.5%) and prescription of either 
vaccine (Gardasil or Cervarix) was 116 health care workers (50.2%). Reasons for 
choice of vaccine included HPV coverage - 42.86%, cost – 13.9% and patient 
choice – 12.1%. Two hundred and four providers (88.3%) indicated that patients 
returned for follow up doses. One hundred and thirty three health care providers 
(44.3%) indicated that patients requested the vaccine. There were 188 health 
care workers who were not aware that Gardasil could be prescribed to males 
(Table II).  
 
Most health care workers (69.7%) believed that the vaccine was effective. Some 
indicated that more media coverage is needed (3.3%),2% feared the side effects, 





Patient’s beliefs with regard to the vaccine as determined by the health care 
worker: 46% were largely unaware of the vaccine, 39.7% believed it is effective 
and prevents cancer, 5.3% believed the doctor, 4% felt that media coverage was 
needed, 2.3% indicated the vaccine would promote promiscuity and 2.7% 
thought the vaccine was too expensive. 
 
Demographics of healthcare workers awareness of the human papillomavirus 
vaccine are shown in Table III. Gynecologists, paediatricians and most general 
practitioners were aware of the HPV vaccine. Thirty seven other specialists  
(75.5%) were aware of the vaccine as well as 30 nurses (60%). The results 
indicated that there was no association between age and awareness, (p = 0.2).  
Males were significantly more aware than females of the vaccine, 96% vs 80% (p 
<0.001). There was also no association between time in practice and awareness 
(p = 0.2).  Health care workers who treated mainly medical aid patients were 
more likely to be aware of the vaccine than those who treated mainly cash- 
paying patients (84% vs. 91%) (p = 0.07). 
 
Uptake of the vaccine among those health care providers who were aware of the 
vaccine is shown in Table IV. Most gynaecologists (96%), paediatricians (94%), 
general practitioners (90.8%) and nurses (100%) prescribed the vaccine. 
However, only 15 other specilaists (40%) prescribed the vaccine.  There was no 




time in practice (p = 0.6) or type of patients being treated either medical aid or 
cash paying (p = 0.9). 
 
Utilisation of the vaccine amongst health care providers who prescribed the 
vaccine is shown in Table V. Results indicate that most health care workers 
prescribed the vaccine less than 10 times. Younger health care workers (< 40 
years) were more likely to prescribe the vaccine 10-20 times, (20%) since 
licensing whereas health care workers 40-60 years of age tended to prescribe 
the vaccine more than 20 times (13%) (p < 0.001). The longer a health care 
worker was in practice (>20 years), the more frequent the vaccine was 




















Cervical cancer is the second most common cancer in women worldwide and the 
most common in developing countries. In Africa it is estimated that 78 897 
women are diagnosed with cervical cancer annually and 61 671 (78%) demise 
from the disease.  HPV types 16 and 18 account for 70% of cervical cancer 
cases worldwide and for 63% of those in South African women.2 The main aim of 
HPV vaccines is primary prevention of HPV infections. Two prophylactic 
vaccines, with a sustained efficacy after 7 years and a good safety profile have 
been licensed in 2008 for use in South Africa for use.  The vaccines currently 
available are a bivalent vaccine targeting HPV 16 and 18 (Cervarix®; 
GlaxoSmithKline) and a quadrivalent vaccine targeting HPV 16, 18, 6 and 11 
(Gardasil®; Merck, Sharpe & Dohme).  
 
Studies regarding knowledge about HPV disease and its prevention vary across 
specialties and seem to correlate with active involvement in screening and with 
the likelihood of having received education about HPV infection and its 
consequences. Gynecologists demonstrated the highest level of knowledge, 
followed by family physicians and paediatricians.63  This study also showed that 
gynaecologists, paediatricians and general practitioners were mostly aware of 




population – young males and females, and they are also involved in counseling 
and treatment about STI’s. Other specialists  seem to be aware of the vaccine 
but largely did not prescribe the vaccine. Nurses are least aware of the vaccine, 
but those that were aware have administered the vaccine to patients. 
 
Health care providers who informed patients about the HPV vaccine comprised 
70%, though 89% of providers were aware of the vaccine. This implies that even 
though they were aware of the vaccine they did not prescribe it. Reasons for this 
could be due to the fact that specialists in various disciplines are more likely to 
deal with specific conditions related to their specialty or that they may not have 
had enough knowledge about the vaccine to counsel patients and prescribe the 
vaccine. Practitioners may not be treating patients holistically but rather targeting 
care to the specific problem that patients present with. They might also expect 
the gynecologist, paediatrician or family practitioner to counsel and offer patients 
the vaccine.   
 
Most physicians believe HPV vaccines should be administered to girls before the 
onset of sexual activity.63  Similarly this study also showed that most physicians 
prescribed the vaccine to females aged 9-26 years. Some health care providers 
prescribed the vaccine to any female or to those who were already sexually 
active.  For maximal effectiveness the vaccine must be given before initiation of 
sexual debut (and potential exposure to HPV).37This implies that even though 




the vaccine is limited and the vaccine is prescribed to the incorrect target 
population. 
 
Even though most clinicians were aware of the vaccine, the majority (77.9%) 
have only prescribed the vaccine less than ten times since licensing in South 
Africa. Only 7.3% of health care providers prescribed the vaccine more than 
twenty times. The health care providers who prescribed the vaccine more than 
twenty times were mostly gynaecologists and nurses. The latter may be due to 
patients with prescriptions from their doctor or that nurses may play a more 
effective role in counseling, screening and practicing preventative medicine. 
Younger practitioners (<40 years of age) mainly prescribed the vaccine less than 
10 times which is surprising as it is assumed that the younger practitioners would 
have more knowledge about the vaccine since it has recently been approved and 
they should be more aware of the impact on cervical cancer morbidity and 
mortality. The longer the duration a clinician was in practice the more times the 
vaccine was prescribed. This could be due to the fact that these providers have 
busy practices or that a rapport has already been established with his/her patient 
and is therefore more comfortable discussing preventative measures. Clinicians 
that have established practices might also be more likely to treat the entire family 
and is thus able to recommend the vaccine to the patients’ children and family. 
 
Patients requesting the vaccine indicated patients’ education and knowledge 




providers indicated that patients requested the vaccine. However, practitioners 
the private sector, treat patients from a higher socioeconomic status than those 
being treated in the public sector. These patients are thus more likely to be 
aware of the vaccines availability. These patients are also more likely to have 
regular Papanicolaou smears and are thus at a lower risk of developing cancer of 
the cervix.  
 
Most practitioners believed that the vaccine is effective. However there were 
some who feared the side effects and who were unsure if it is effective. It is also 
believed by some practitioners that more media coverage is needed and that the 
vaccine is expensive.  The bivalent vaccine Cervarix®, was chosen by some 
practitioners mainly because of the cost of the vaccine. A recent study has also 
shown that physicians identified cost as a barrier to patient acceptance.66 The 
cost of the vaccine and availability represent important system-based factors that 
could inhibit vaccine uptake – cash paying patients may find the vaccine 
expensive. A study in South Africa showed that adding the HPV vaccine to the 
current cervical cancer screening strategy is cost-effective.62 Vaccination can 
therefore reduce the cost of cervical cancer to the burdened health system and to 
the patient.61 A few of surveyed health care workers (1%) believed that 
vaccination against HPV could unintentionally encourage risky sexual practices 
amongst patients vaccinated. This was more an anticipated concern among 





Health care providers believed that patients 46% were largely unaware of the 
vaccine and 39% believed it is effective. Some also believed what the health care 
provider had told them. These results indicate that patients need to be counseled 
with regards to the vaccine. Health care practitioners provide patients with 
important information and parents value advice about preventative measure such 
as vaccines. The HPV vaccination programs success rely mostly on health care 
providers’ willingness and ability to recommend vaccination against HPV to their 
patients. This includes the ability to give information with regards to the 
advantages of vaccination to adolescents and their parents.18 Adequate 
counseling and information should be given to patients and parents of 
adolescents by health care workers as most are unaware or do not have enough 
knowledge with regards to the HPV vaccine since it is relatively new. Educational 
information to parents should be personalised taking into account the patients 
background knowledge and the information needs of the patient. The main 
emphasis should be that HPV vaccines do not cure cancer but prevent the most 
common HPV-related cancers and that they are most effective when given 
before the onset of sexual activity. In addition counseling is needed with regards 
to vaccine delivery i.e. three doses are required and it does not prevent Human 
Immunodeficiency Virus infection or other sexually transmitted infections. The 
importance of physician counseling is imperative as studies demonstrate that 
following counseling, more parents are in favor of vaccination.59 HPV vaccine 
uptake may be affected by factors related to patient-provider communication. The 




personal experiences may influence patient and caregiver acceptance of 
vaccine.64 
 
Most health care providers were unaware that Gardasil ® is registered for use in 
males as well. Practitioners that feel more comfortable vaccinating females than 
males might believe that vaccination against HPV will have a more important 
impact on female health. These beliefs are however not consistent with data 
which has shown that administering the vaccine to males and females is more 
successful in decreasing the load of disease with HPV than administering the 
vaccine to females only.65 Health care worker education is needed about the 
importance of immunizing both genders. Promoting awareness of the association 
between HPV and cancer of the male genital tract, oral cavity, oropharynx, and 
larynx might be a more beneficial way to encourage vaccination. Although health 
care providers are aware of the vaccine and prescribe it, they are unaware of its 
recommended use. 
 














General awareness with regards to the vaccine amongst health care workers 
appears to be sufficient. Counseling of patients regarding the availability of the 
vaccine and practicing preventative medicine seems to be a concern amongst 
health care workers. This could be due to time constraints, inability to discuss a 
vaccine with adolescents and their parents, cost issues or simply that even 
though they are aware a vaccine exists they are not counseling patients about it. 
Many expect patients to request the vaccine and expect that patients should 
have some knowledge prior to the health care worker discussing the vaccine. 
Patients’ may not see the long term need for the vaccine as there is no 
immediate gain and benefits are only detected later in life. Many health care 
workers believe that public education campaigns such as schools and the media 
should be in progress so that patients are aware of the vaccines availability. 
 
Knowledge about the vaccine seems to be lacking (most are unaware the 
vaccine can be given to males and the vaccine seems to be prescribed to 
females of any age-group regardless if they were already sexually active). Health 
care providers need more education about the available vaccines and differences 





























APPENDIX a - Questionnaire 
Study No:  ____________________________ 
1. Designation:   Gynaecologist =1    Paediatrician =2    General Practitioner =3     Other 
medical doctor =4           Nurse=5 
2. Age:       < 40 =1         40-60 =2           >60 =3 
3. Sex:  Male =1  Female =2 
4. How long are you practicing?    <10 years =1    10-20 yrs =2       >20yrs=3 
5. Patients being treated mostly cash or medical aid?  Cash =1   Medical Aid =2 
6. Aware of cervical screening programme in SA :   Yes =1   No =2 
7. Aware that there is a vaccine for genital warts/precancerous cervical lesions/cancer 
caused by HPV?      Yes =1  No=2 
8. Do you inform patients of HPV related diseases?     Yes =1  No =2    
9. Do you inform patients of the availability of the HPV vaccine yes =1   No = 2 
10. Do you prescribe the vaccine on request?   Yes = 1  No = 2 
a) If NO why? 
________________________________________________________________ 
b.)   If YES, target population: (eg. Sex, age)   
___________________________________________________________ 
 
11. If using the vaccine, how many time have you prescribed the vaccine since licensing :              
<10 times =1    10-20 times =2,    >20 times =3   N/A = 4 
12. Are you aware that the vaccine (Gardasil) can be prescribed to males  Yes =1   No = 2  
13. Do patients request the vaccine?   Yes =1  No =2  
14. Which vaccine do you prescribe: Gardasil =1   Cervarix =2   Either =3     N/A=4 
15. Reasons for your choice of vaccine: Cost =1      HPV coverage =2         Patient choice =3            
All =4     Other =5      N/A =6 
16. Are patients coming back for follow up dose:  Yes =1      No =2       N/A =3 
17. Beliefs regarding the HPV vaccine: (barriers/concerns/recommendations/comment) 
a) (Own beliefs) 
_______________________________________________________________________
________________________________________________________ 































 Frequency Percentage (%) 
Age:   <40 94 31.3 
           40-60 159 53 
           >60 47 15.7 
Sex:     Male 167 55.7 
            Female 133 44.3 
Time Practicing:    <10 years 94 31.3 
                                 10-20 years 138 46 
                                 >20 years 68 22.7 
Patients being treated:  Cash 103 34.3 




TABLE II  
 
Knowledge and awareness of the human papillomavirus vaccine 
among healthcare workers 
 
 Frequency Percentage (%) 






                  No 20 6.7 
   
Aware of HPV vaccine: Yes 267 89 
                                           No 33 11 
   
Inform of HPV vaccine: Yes 181 60.3 
                                           No 119 39.7 
   
Prescribe vaccine: Yes 231 86.5 
                                   No 86 13.5 
   
Vaccine used: Gardasil®  100 43.3 
                         Cervarix® 15 6.5 
                         Either 116 50.2 
   
Reasons for choice: Cost 32 13.9 
                                 HPV coverage 99 42.9 
                                 Patient choice 28 12.1 
                                 All 65 28.1 
                                 Other 5 2.1 
   
Patients request vaccine: Yes 133 44.3 
                                                No 167 55.7 
   
Own beliefs: Effective 209 69.7 
                      Unsure 37 12.3 
                      Media coverage 10 3.3 
                      Fear of side effects 6 2 
                      Promotes promiscuity 3 1 
                      Expensive 9 3 
                      Not aware of vaccine 26 8.7 











Demographics of healthcare workers awareness of the human 
papillomavirus vaccine 
 
 YES NO 
Designation: Gynaecologist 
 
50 (100%) 0 
                        Paediatrician 
 
52 (100%) 0 
                        General Practitioner 
 
98 (98.9%) 1 (1%) 
                        Other medical doctor 
 
37 (75.5%) 12 (24.5%) 
                        Nurses 30 (60%) 20 (40%) 
   
Age: <40 
 
88 (93%) 6 (6.4%) 
         40-60 
 
137 (86.2%) 22 (13.8%) 
        >60 42 (89.3%) 5 (10.6%) 
   
Sex: Male 
 
160 (95.8%) 7 (4.2%) 
        Female 107 (80.5%) 26 (19.6%) 
   
Time practicing: <10 years 
 
88 (93.6%) 6  (6.4%) 
                              10-20 years 
 
121 (87.8%) 17 (12.3%) 
                              >20 years 58 (85.3%) 10 (14.7%) 
   
Patients treated: Medical Aid 
 
180 (91.5%) 17 (8.6%) 
                               Cash 87 (84.5%) 16 (15.5%) 













Uptake of the human papillomavirus vaccine among providers 
who were aware of it 
 
 YES NO 
Designantion: Gynaecologist 
 
48 (96%) 2 (4%) 
                           Paediatrician 
 
49 (94.2%) 3 (5.7%) 
                           General Practitioner 
 
89 (90.8%) 9 (9.1%) 
                           Other medical doctor 
 
15 (40.5%) 22 (59.46%) 
                           Nurses  30 (100%) 0 
   
Age: <40 
 
74 (84%) 14 (15.9%) 
          40-60  
  
120 (87.6%) 17 (12.4%) 
          >60 37 (88.1%) 5 (11.9%) 
   
Sex: Male 
 
135 (84.4%) 25 (15.6%) 
        Female   96 (89.7%) 11 (10.3%) 
   
Time practicing: <10 years 
 
74 (84.1%) 14 (15.9%) 
                              10-20 years 
 
107 (88.43%) 14 (11.6%) 
                              >20 years 50 (86.2%) 8 (13.8%) 
   
Patients treated: Medical Aid 
 
156 (86.6%) 24 (13.3%) 
                                Cash 75 (86.2%) 12 (13.8%) 










Frequency of vaccine prescription by healthcare workers 
 
Number of times prescribed vaccine 
 <10  10-20 times >20 times 
Designation: Gynaecologist 
 
26 (54.1%) 14 (29.1%) 8 (16.7%) 
                         Paediatrician 
 
46 (93.8%) 2 (4.1%) 1 (2%) 
                         General Practitioner 
 
81 (91.1%) 3 (3.4%) 0 
                         Other medical doctor 
 
13 (86.7%) 1 (6.7%) 1 (6.7%) 
                         Nurses 
 
14 (46.7%) 7 (23.3%) 7 (23.3%) 
TOTAL 180 (77. 9%) 29 (12.6%) 17 (7.4%) 
    
Age: <40 
 
59 (79.7%) 15 (20.3%) 0 
          40-60 
 
92 (76.7%) 11 (9.2%) 16 (13.3%) 
         >60 
 
29 (78.4%) 3 (8.1%) 1 (2.7%) 
TOTAL 180 (77.9%) 29 (12.6%) 17 (7.36%) 
    
Sex: Male 
 
107 (79.3%) 15 (11.1%) 11 (8.2%) 
         Female 
 
73 (76%) 14 (14.6%) 6 (6.3%) 
TOTAL 180 (77.9%) 29 (12.6%) 17(7.4%) 
    
Time practicing: <10 years 
 
62 (83.8%) 12 (16.2%) 0 
                              10-20 years 
 
84 (74.5%) 13 (12.2%) 9 (8.4%) 
                              >20 years 
 
34 (68%) 4 (8%) 8 (16%) 
TOTAL 180 (77.9% 29 (12.5%) 17 (7.4%) 
    
Patients treated: Medical Aid 
 
121 (77.6%) 18 (11.5%) 2 (2.7%) 
                                 Cash 
 
59 (78.7%) 11 (14.7%) 15 (9.6%) 
TOTAL 
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